AB0409 IMPROVEMENT IN PAIN-ASSOCIATED BIOMARKERS WITH DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA) IN A DOUBLE-BLIND PHASE 2 STUDY (IM011-084)

P J Mease,C T Ritchlin,L Gao,P Schafer,M Nowak,I M Catlett,J Liu

doi:10.1136/annrheumdis-2024-eular.1877

AB0409 IMPROVEMENT IN PAIN-ASSOCIATED BIOMARKERS WITH DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA) IN A DOUBLE-BLIND PHASE 2 STUDY (IM011-084)

P J Mease, C T Ritchlin + Show 5 more

https://doi.org/10.1136/annrheumdis-2024-eular.1877

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2024

#Changes In Biomarkers #Greater Improvement In Pain Score #Improvement In Pain Score #Pharmacodynamic Changes #Pain Score In Patients #Baseline Pain Score #Mease PJ #Poorer Response In Patients #Pain Score #Change In Pain Score

Abstract
Full-Text
Similar Papers

Abstract

Listen

Background:Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA.[1] Pain has been reported to be a more important predictor...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

AB0409 IMPROVEMENT IN PAIN-ASSOCIATED BIOMARKERS WITH DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA) IN A DOUBLE-BLIND PHASE 2 STUDY (IM011-084)